Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyBaylor Scott & White Lenmeldy Coverage Prior Auth …
    Ask Trek AI about this page
    CurrentBaylor Scott & White Health PlanPolicy 309

    Atidarsagene autotemcel (Lenmeldy) — Medical Coverage Policy

    Customize your policy alerts

    Sign up for Baylor Scott & White Health Plan Policy 309 alerts

    Get alerted when Policy 309 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage and prior authorization requirements for atidarsagene autotemcel (Lenmeldy) for treatment of metachromatic leukodystrophy (MLD) in pediatric patients; applies when member benefits include the drug per plan documents.

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyAtidarsagene autotemcel (Lenmeldy) — Medical Coverage Policy
    Policy CodePolicy 309
    Change TypeNo material clinical or coverage changes
    Effective DateAug 1, 2026
    Last ReviewJul 23, 2026
    Next Review DateJul 23, 2027
    Key ActionObtain prior authorization and provide required diagnostic and clinical documentation demonstrating ARSA deficiency, sulfatide presence, genotype consistent with eligible MLD form, and treatment center attestation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    RequiredPrior authorization status
    one lifetimeTreatment courses authorized
    E75.25ICD-10
    J3391HCPCS/J-code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Atidarsagene Autotemcel (Lenmeldy)

    Initial Treatment Criteria

    Covered when ALL of the following are met

    Diagnosis of MLD: Member has diagnosis of metachromatic leukodystrophy (MLD) as evidenced by BOTH: (a) ARSA activity below the normal range in peripheral blood mononuclear cells or fibroblasts AND (b) presence of sulfatides in 24-hour urine collection to exclude MLD carriers and patients with ARSA pseudo-deficiency.
    Eligible MLD forms: Member meets criteria for one of: (a) Pre-symptomatic late infantile (PSLI): ARSA genotype consistent with late infantile MLD (two null mutant ARSA alleles) AND pre-symptomatic clinical status at time of treatment (absence of neurological impairment; may have instrumental signs on electroneurography or brain MRI) OR (b) Early juvenile: ARSA genotype consistent with early juvenile MLD (one null and one residual mutant ARSA allele) AND either (1) pre-symptomatic (absence of neurological signs; exam may be limited to abnormal reflexes and/or clonus) OR (2) early symptomatic with neurological signs AND intelligence quotient ≥85 AND retaining ability to walk independently for ≥10 steps AND age <7 years at time of symptom onset.IQ >= 85; independent walking >= 10 steps; age of symptom onset <7 years
    Provider and treatment logistics: Medication is prescribed by or in consultation with a pediatric neurologist or specialist in MLD; member has been assessed to be an appropriate candidate for apheresis; provider attests member will receive atidarsagene autotemcel at a qualified treatment center.
    Exclusionary clinical conditions: Member does NOT have any of the following: positive screening for HBV, HCV, HTLV-1/2, HIV-1/2, CMV, or mycoplasma; recent antiretroviral medication use (within time needed for expected total elimination of medication OR 30 days, whichever is longer); hematopoietic stem cell transplant within previous 6 months or evidence of residual donor cells; neoplastic disease (e.g., myelodysplastic syndrome or acute myelogenous leukemia); previous atidarsagene autotemcel treatment; diagnosis of early symptomatic late infantile, late juvenile, or adult MLD; entering MLD rapid phase of decline evidenced by loss of ability to walk.

    Only one lifetime treatment is considered medically necessary; repeat administration is experimental/investigational.

    Diagnosis of early symptomatic late infantile, late juvenile, or adult MLD is an explicit exclusion for coverage under these criteria. Members with these diagnoses do not meet the policy’s initial treatment criteria and are not eligible for atidarsagene autotemcel under this coverage guidance.

    Repeat administration of atidarsagene autotemcel is considered experimental and investigational and therefore not medically necessary. Baylor Scott & White Health Plan authorizes only one treatment per lifetime; effectiveness of repeat dosing has not been established.

    Relevant Procedure and Diagnosis Codes

    Covered CPT/HCPCS CodesmixedCovered
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour
    96366Intravenous infusion; each additional hour
    96413Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
    96415Chemotherapy administration, intravenous infusion technique; each additional hour
    J3391Injection, atidarsagene autotemcel, per treatment
    Applicable ICD-10 CodesICD-10
    E75.25Metachromatic leukodystrophy

    Provider Requirements, Prior Authorization, and Denial Risks

    Prior Authorization

    Prior authorization required for atidarsagene autotemcel

    Prior authorization is required for atidarsagene autotemcel (Lenmeldy). Applicable billing codes include J3391 for the drug and the listed infusion/chemotherapy administration CPT codes (96365, 96366, 96413, 96415).

    • Drug HCPCS: J3391 — Injection, atidarsagene autotemcel, per treatment
    • CPT: 96365, 96366, 96413, 96415 — infusion/chemotherapy administration codes
    Note

    Provider prescribing and treatment logistics

    Medication must be prescribed by or in consultation with a pediatric neurologist or MLD specialist; provider must attest the member will receive treatment at a qualified treatment center and that the member is an appropriate candidate for apheresis.

    • Prescribing physician: pediatric neurologist or specialist in MLD
    • Attestation: treatment at a qualified treatment center

    Background on Metachromatic Leukodystrophy (MLD)

    Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disease caused by defects in the ARSA gene leading to deficient arylsulfatase A activity and accumulation of sulfatides, which produce progressive central and peripheral demyelination with cognitive and motor decline. MLD is classified by age of onset (late infantile, juvenile, adult) and clinical course; atidarsagene autotemcel is an autologous hematopoietic stem/progenitor cell (HSPC) gene therapy intended to restore ARSA activity. Policy coverage is limited to specific early forms of MLD and requires specialist involvement, apheresis candidacy, treatment at a qualified center, and absence of listed infectious, hematologic, neoplastic, prior-treatment, or rapid-decline exclusionary conditions.

    Definitions and Phenotype Categories

    Pre-symptomatic late infantile (PSLI) — definition and genotype criteria
    Genotype requirementARSA genotype consistent with late infantile MLD (two null mutant ARSA alleles)
    Clinical status at treatmentPre-symptomatic: absence of neurological impairment (disease-related symptoms) at time of treatment
    Permissible instrumental findingsMay have disease signs on instrumental evaluations (electroneurography or brain MRI) despite absence of clinical neurological impairment
    ContextThis definition applies to classification of eligible MLD forms for atidarsagene autotemcel coverage
    Early juvenile — genotype and pre-symptomatic/early symptomatic definitions
    Genotype requirementARSA genotype consistent with early juvenile MLD (one null and one residual mutant ARSA allele)

    Policy Dates and Revision History

    2026-08-01Effective dateLatest

    Policy became effective with coverage criteria defining prior authorization requirements and clinical eligibility for atidarsagene autotemcel (Lenmeldy).

    2026-07-23Review

    Policy last reviewed; clarified one treatment per lifetime authorized and simplified the background section.

    2025-08-11Update
    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyAtidarsagene autotemcel (Lenmeldy) — Medical Coverage Policy
    Policy CodePolicy 309
    Change TypeNo material clinical or coverage changes
    Effective DateAug 1, 2026
    Last ReviewJul 23, 2026
    Next Review DateJul 23, 2027
    Key ActionObtain prior authorization and provide required diagnostic and clinical documentation demonstrating ARSA deficiency, sulfatide presence, genotype consistent with eligible MLD form, and treatment center attestation.
    SourceLink
    On This Page
    Coverage Criteria for Atidarsagene Autotemcel (Lenmeldy)Relevant Procedure and Diagnosis CodesProvider Requirements, Prior Authorization, and Denial RisksBackground on Metachromatic Leukodystrophy (MLD)Definitions and Phenotype CategoriesPolicy Dates and Revision History
  1. Assessment: documented apheresis candidacy
  2. Documentation Required

    Required clinical documentation to support medical necessity

    Documentation submitted with prior authorization must demonstrate diagnostic confirmation of MLD and relevant clinical assessments.

    • ARSA enzyme activity below the normal range in peripheral blood mononuclear cells or fibroblasts
    • Presence of sulfatides in a 24-hour urine collection
    • ARSA genotype consistent with the required MLD subtype (two null alleles for PSLI; one null and one residual allele for early juvenile)
    • Neurologic status and, when applicable, IQ (≥85) and ambulatory ability (independent walking ≥10 steps)
    • Documentation of apheresis candidacy and treatment center attestation
    • Absence of excluded infections/conditions per policy
    Denial Risk

    Repeat treatment denial risk — only one lifetime treatment allowed

    Only one atidarsagene autotemcel treatment per member is considered medically necessary; requests for repeat administration will be denied as experimental/investigational.

    • BSWHP considers only one treatment per lifetime medically necessary
    • Repeat administration is labeled experimental and investigational and not covered
    Denial Risk

    Non-MLD indications will be denied

    Requests for use of atidarsagene autotemcel for indications other than metachromatic leukodystrophy (MLD) will be considered experimental and investigational and denied.

    • Treatment for all other indications is considered experimental and investigational by BSWHP
    Pre-symptomatic definitionAbsence of neurological signs and symptoms of MLD or physical exam findings limited to abnormal reflexes and/or clonus
    Early symptomatic definitionPresence of neurological signs and symptoms of MLD AND intelligence quotient ≥85 AND ability to walk independently for ≥10 steps
    Age threshold for symptom onsetAge less than 7 years at time of symptom onset (required for early symptomatic status)
    ContextEither pre-symptomatic or early symptomatic criteria (with genotype) qualify under the policy for early juvenile MLD

    Updated HCPCS code and removed Medicare NCD/LCD InterQual statement for clarity.

    2025-04-14Update

    Updated treatment center criteria to attestation only, made minor formatting changes, and updated ending note sections to align with CMS requirements and business entity changes.

    2024-06-10New policy

    Policy created as a new medical coverage policy for atidarsagene autotemcel (Lenmeldy).